TNF-α inhibition reduces renal injury in DOCA-salt hypertensive rats

Ahmed Abdelrazik Elmarakby, Jeffrey E. Quigley, John D. Imig, Jennifer S. Pollock, David M. Pollock

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Studies suggest that the inflammatory cytokine TNF-α plays a role in the prognosis of end-stage renal diseases. We previously showed that TNF-α inhibition slowed the progression of hypertension and renal damage in angiotensin II salt-sensitive hypertension. Thus, we hypothesize that TNF-α contributes to renal inflammation in a model of mineralocorticoid- induced hypertension. Four groups of rats (n = 5 or 6) were studied for 3 wk with the following treatments: 1) placebo, 2) placebo + TNF-α inhibitor etanercept (1.25 mg·kg-1·day-1 sc), 3) deoxycorticosterone acetate + 0.9% NaCl to drink (DOCA-salt), or 4) DOCA-salt + etanercept. Mean arterial blood pressure (MAP) measured by telemetry increased in DOCA-salt rats compared with baseline (177 ± 4 vs. 107 ± 3 mmHg; P < 0.05), and TNF-α inhibition had no effect in the elevation of MAP in these rats (177 ± 8 mmHg). Urinary protein excretion significantly increased in DOCA-salt rats compared with placebo (703 ± 76 vs. 198 ± 5 mg/day); etanercept lowered the proteinuria (514 ± 64 mg/day; P < 0.05 vs. DOCA-salt alone). Urinary albumin excretion followed a similar pattern in each group. Urinary monocyte chemoattractant protein (MCP)-1 and endothelin (ET)-1 excretion were also increased in DOCA-salt rats compared with placebo (MCP-1: 939 ± 104 vs. 43 ± 7 ng/day, ET-1: 3.30 ± 0.29 vs. 1.07 ± 0.03 fmol/day; both P < 0.05); TNF-α inhibition significantly decreased both MCP-1 and ET-1 excretion (409 ± 138 ng/day and 2.42 ± 0.22 fmol/day, respectively; both P < 0.05 vs. DOCA-salt alone). Renal cortical NF-κB activity also increased in DOCA-salt hypertensive rats, and etanercept treatment significantly reduced this effect. These data support the hypothesis that TNF-α contributes to the increase in renal inflammation in DOCA-salt rats.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Regulatory Integrative and Comparative Physiology
Volume294
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Desoxycorticosterone Acetate
Salts
Kidney
Wounds and Injuries
Chemokine CCL2
Arterial Pressure
Endothelin-1
Placebos
Hypertension
Inflammation
Desoxycorticosterone
Telemetry
Mineralocorticoids
Renal Hypertension
Proteinuria
Angiotensin II
Chronic Kidney Failure
Albumins
Acetates

Keywords

  • Blood pressure
  • Deoxycorticosterone acetate
  • Etanercept
  • Nuclear factor-κB
  • Renal inflammation
  • Tumor necrosis factor-α

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

TNF-α inhibition reduces renal injury in DOCA-salt hypertensive rats. / Elmarakby, Ahmed Abdelrazik; Quigley, Jeffrey E.; Imig, John D.; Pollock, Jennifer S.; Pollock, David M.

In: American Journal of Physiology - Regulatory Integrative and Comparative Physiology, Vol. 294, No. 1, 01.01.2008.

Research output: Contribution to journalArticle

@article{ab7cac348a6d4555b3f7a8c15c05cd9c,
title = "TNF-α inhibition reduces renal injury in DOCA-salt hypertensive rats",
abstract = "Studies suggest that the inflammatory cytokine TNF-α plays a role in the prognosis of end-stage renal diseases. We previously showed that TNF-α inhibition slowed the progression of hypertension and renal damage in angiotensin II salt-sensitive hypertension. Thus, we hypothesize that TNF-α contributes to renal inflammation in a model of mineralocorticoid- induced hypertension. Four groups of rats (n = 5 or 6) were studied for 3 wk with the following treatments: 1) placebo, 2) placebo + TNF-α inhibitor etanercept (1.25 mg·kg-1·day-1 sc), 3) deoxycorticosterone acetate + 0.9{\%} NaCl to drink (DOCA-salt), or 4) DOCA-salt + etanercept. Mean arterial blood pressure (MAP) measured by telemetry increased in DOCA-salt rats compared with baseline (177 ± 4 vs. 107 ± 3 mmHg; P < 0.05), and TNF-α inhibition had no effect in the elevation of MAP in these rats (177 ± 8 mmHg). Urinary protein excretion significantly increased in DOCA-salt rats compared with placebo (703 ± 76 vs. 198 ± 5 mg/day); etanercept lowered the proteinuria (514 ± 64 mg/day; P < 0.05 vs. DOCA-salt alone). Urinary albumin excretion followed a similar pattern in each group. Urinary monocyte chemoattractant protein (MCP)-1 and endothelin (ET)-1 excretion were also increased in DOCA-salt rats compared with placebo (MCP-1: 939 ± 104 vs. 43 ± 7 ng/day, ET-1: 3.30 ± 0.29 vs. 1.07 ± 0.03 fmol/day; both P < 0.05); TNF-α inhibition significantly decreased both MCP-1 and ET-1 excretion (409 ± 138 ng/day and 2.42 ± 0.22 fmol/day, respectively; both P < 0.05 vs. DOCA-salt alone). Renal cortical NF-κB activity also increased in DOCA-salt hypertensive rats, and etanercept treatment significantly reduced this effect. These data support the hypothesis that TNF-α contributes to the increase in renal inflammation in DOCA-salt rats.",
keywords = "Blood pressure, Deoxycorticosterone acetate, Etanercept, Nuclear factor-κB, Renal inflammation, Tumor necrosis factor-α",
author = "Elmarakby, {Ahmed Abdelrazik} and Quigley, {Jeffrey E.} and Imig, {John D.} and Pollock, {Jennifer S.} and Pollock, {David M.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1152/ajpregu.00466.2007",
language = "English (US)",
volume = "294",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "1",

}

TY - JOUR

T1 - TNF-α inhibition reduces renal injury in DOCA-salt hypertensive rats

AU - Elmarakby, Ahmed Abdelrazik

AU - Quigley, Jeffrey E.

AU - Imig, John D.

AU - Pollock, Jennifer S.

AU - Pollock, David M.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Studies suggest that the inflammatory cytokine TNF-α plays a role in the prognosis of end-stage renal diseases. We previously showed that TNF-α inhibition slowed the progression of hypertension and renal damage in angiotensin II salt-sensitive hypertension. Thus, we hypothesize that TNF-α contributes to renal inflammation in a model of mineralocorticoid- induced hypertension. Four groups of rats (n = 5 or 6) were studied for 3 wk with the following treatments: 1) placebo, 2) placebo + TNF-α inhibitor etanercept (1.25 mg·kg-1·day-1 sc), 3) deoxycorticosterone acetate + 0.9% NaCl to drink (DOCA-salt), or 4) DOCA-salt + etanercept. Mean arterial blood pressure (MAP) measured by telemetry increased in DOCA-salt rats compared with baseline (177 ± 4 vs. 107 ± 3 mmHg; P < 0.05), and TNF-α inhibition had no effect in the elevation of MAP in these rats (177 ± 8 mmHg). Urinary protein excretion significantly increased in DOCA-salt rats compared with placebo (703 ± 76 vs. 198 ± 5 mg/day); etanercept lowered the proteinuria (514 ± 64 mg/day; P < 0.05 vs. DOCA-salt alone). Urinary albumin excretion followed a similar pattern in each group. Urinary monocyte chemoattractant protein (MCP)-1 and endothelin (ET)-1 excretion were also increased in DOCA-salt rats compared with placebo (MCP-1: 939 ± 104 vs. 43 ± 7 ng/day, ET-1: 3.30 ± 0.29 vs. 1.07 ± 0.03 fmol/day; both P < 0.05); TNF-α inhibition significantly decreased both MCP-1 and ET-1 excretion (409 ± 138 ng/day and 2.42 ± 0.22 fmol/day, respectively; both P < 0.05 vs. DOCA-salt alone). Renal cortical NF-κB activity also increased in DOCA-salt hypertensive rats, and etanercept treatment significantly reduced this effect. These data support the hypothesis that TNF-α contributes to the increase in renal inflammation in DOCA-salt rats.

AB - Studies suggest that the inflammatory cytokine TNF-α plays a role in the prognosis of end-stage renal diseases. We previously showed that TNF-α inhibition slowed the progression of hypertension and renal damage in angiotensin II salt-sensitive hypertension. Thus, we hypothesize that TNF-α contributes to renal inflammation in a model of mineralocorticoid- induced hypertension. Four groups of rats (n = 5 or 6) were studied for 3 wk with the following treatments: 1) placebo, 2) placebo + TNF-α inhibitor etanercept (1.25 mg·kg-1·day-1 sc), 3) deoxycorticosterone acetate + 0.9% NaCl to drink (DOCA-salt), or 4) DOCA-salt + etanercept. Mean arterial blood pressure (MAP) measured by telemetry increased in DOCA-salt rats compared with baseline (177 ± 4 vs. 107 ± 3 mmHg; P < 0.05), and TNF-α inhibition had no effect in the elevation of MAP in these rats (177 ± 8 mmHg). Urinary protein excretion significantly increased in DOCA-salt rats compared with placebo (703 ± 76 vs. 198 ± 5 mg/day); etanercept lowered the proteinuria (514 ± 64 mg/day; P < 0.05 vs. DOCA-salt alone). Urinary albumin excretion followed a similar pattern in each group. Urinary monocyte chemoattractant protein (MCP)-1 and endothelin (ET)-1 excretion were also increased in DOCA-salt rats compared with placebo (MCP-1: 939 ± 104 vs. 43 ± 7 ng/day, ET-1: 3.30 ± 0.29 vs. 1.07 ± 0.03 fmol/day; both P < 0.05); TNF-α inhibition significantly decreased both MCP-1 and ET-1 excretion (409 ± 138 ng/day and 2.42 ± 0.22 fmol/day, respectively; both P < 0.05 vs. DOCA-salt alone). Renal cortical NF-κB activity also increased in DOCA-salt hypertensive rats, and etanercept treatment significantly reduced this effect. These data support the hypothesis that TNF-α contributes to the increase in renal inflammation in DOCA-salt rats.

KW - Blood pressure

KW - Deoxycorticosterone acetate

KW - Etanercept

KW - Nuclear factor-κB

KW - Renal inflammation

KW - Tumor necrosis factor-α

UR - http://www.scopus.com/inward/record.url?scp=38148999322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38148999322&partnerID=8YFLogxK

U2 - 10.1152/ajpregu.00466.2007

DO - 10.1152/ajpregu.00466.2007

M3 - Article

C2 - 17989143

AN - SCOPUS:38148999322

VL - 294

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 1

ER -